Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Bullboard Posts
Comment by PoorOpinionon May 08, 2018 1:47pm
215 Views
Post# 27999016

RE:RE:RE:RE:RE:RE:Where is it best to find Taimed's monthly revenue

RE:RE:RE:RE:RE:RE:Where is it best to find Taimed's monthly revenue
SPCEO1 wrote:
PoorOpinion wrote: I think I found it.

Go here, this is the taipei exchange official monthly stats page.
https://www.tpex.org.tw/web/regular_emerging/statistics/monthly_statistics.php?l=en-us

Click the third link, change the dates to get a monthly xl doc (the May one isnt there yet but you can get earlier ones). When you open the xl doc Taimed isnt listed with other biotech stocks (21) but in 
22 Internet/Communication (why?? did they list via shell company???)

As you said looks like they have no revenue for the 2018 months so far but something for 2017.


Thanks for that. But it looks like they must have gotten an exemption from posting the monthly revenue numbers or they just ahve not had any revenue this year so far. It will be intersting to see if any data pops up for April. 


Its certainly very confusing to me. The way I understand it is

Jan 2017 ( and proceeding months) 208 per month
12 month period Feb2017-Jan2018 802 per month
Feb-Mar2018 0 per month

It looks like 2017 they are taking one payment like a royalty/milestone and splitting it over a full year, this runs out Jan 2018 and they arent reporting any revenue after that. Here's some things I'm wondering about.

1) The contract states Thera order drug from Taimed on a quarterly basis. So will the revenue from that show up in Apr number or will they divide that order over 3 months?
2) They will have to start accounting for the 5million(?) in shares they get, clearly they didnt put that in the Feb/Mar numbers does that kick in with the drug sales in Apr?
3) The drug revenue, as you said before, may represent filling the distribution system more than real sales to patients.

I think unless they actually indicate in some way how many patients have applied for or are taking the drug then any number we try to estimate based on a simple monthly revenue is going to be full of pretty large caveats. 

Bullboard Posts